Background-Data on the association between glycemic control after percutaneous coronary intervention and clinical outcomes are limited and controversial in diabetic patients. Methods and Results-We studied 980 patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention using drug-eluting stents. Based on 2-year glycosylated hemoglobin A (HbA1c) levels, we divided patients into 2 groups of HbA1c<7.0 (n=489) and HbA1c≥7.0 (n=491). Propensity score-matched analysis was performed in 322 pairs. The primary outcome was major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of cardiac death, myocardial infarction, repeat revascularization, or stroke. Median follow-up duration was 5.4 years. The 7-year incidence of MACCE was lower in the HbA1c<7.0 group than in the HbA1c≥7.0 group (26.9% versus 40.3%; adjusted hazard ratio, 0.75; 95% confidence interval, 0.57-0.98; P=0.03). After propensity score matching, the 7-year incidence of MACCE was still lower in the HbA1c<7.0 group than in the HbA1c≥7.0 group (27.5% versus 37.4%; hazard ratio, 0.71; 95% confidence interval, 0.52-0.97; P=0.03), mainly because of a reduction in repeat revascularization (19.9% versus 29.5%; hazard ratio, 0.66; 95% confidence interval, 0.47-0.93; P=0.02). In subgroup analyses, the benefit of glycemic control for MACCE was more prominent in patients with residual SYNTAX score (Synergy Between PCI With Taxus and Cardiac Surgery) >4 than in those with the residual SYNTAX score ≤4 (P interaction =0.004). Conclusions-HbA1c<7.0 measured 2 years after percutaneous coronary intervention was associated with a reduced rate of MACCE. Our data suggest that high HbA1c levels 2 years after percutaneous coronary intervention may identify a population at increased risk of adverse events, especially repeat revascularization. (Circ Cardiovasc Interv.
C ardiovascular disease is the major cause of mortality in patients with type 2 diabetes mellitus. 1 Although intensive therapy to lower glucose has consistently been reported to reduce microvascular complications of type 2 diabetes mellitus, 2, 3 whether intensive glycemic control reduces macrovascular complications and improves clinical outcomes remains controversial. 4, 5 Limited data are available regarding the effect of intensive glycemic control for secondary prevention in patients with established cardiovascular disease, especially in those undergoing percutaneous coronary intervention (PCI). The association between baseline glycosylated hemoglobin A (HbA1c) at the time of PCI and clinical outcomes among diabetic patients was reported in a few studies with conflicting results. 6, 7 Moreover, it is not known if glycemic control after PCI can improve cardiovascular outcomes, which is a more important issue than glycemic status at the time of PCI. Because diabetic patients account for more than a quarter of all patients undergoing PCI and have worse outcomes compared with nondiabetic patients, 8, 9 determining the optimal strategy for glycemic control in these patients after PCI has substantial clinical implications. Therefore, we investigated the association between glycemic status as estimated by HbA1c measured 2 years after PCI and long-term cardiovascular outcomes in type 2 diabetic patients undergoing PCI using drug-eluting stents (DES). Glycemic Control After PCI in DM
Methods

Study Population
Between January 2003 and December 2011, a total of 5819 consecutive patients underwent PCI with DES for coronary artery disease at Samsung Medical Center. Patients with a prior history of coronary artery bypass graft surgery were excluded. A total of 1399 patients with type 2 diabetes mellitus were included. Of these, 980 patients who had available HbA1c data at the time of PCI (baseline) and 2 years after PCI (follow-up) were analyzed in this study ( Figure 1 ). The HbA1c levels measured 2 years after PCI were chosen as follow-up data that reflected the stabilized and long-term status of glycemic control. Baseline characteristics, angiographic and procedural findings, and clinical outcome data were collected prospectively in our PCI registry by research coordinators. Patients were routinely followed up at 1, 6, and 12 months after the index procedure and annually thereafter. Further information was collected by telephone contact or medical records if necessary. Electronic medical record system has been used in our center since 1999, but laboratory data including HbA1c after 1994 can be accessed by electronic medical record. The institutional review board of Samsung Medical Center approved this study and waived the requirement for written informed consent for access to an institutional registry.
Percutaneous Coronary Intervention
PCI was performed according to current practice guidelines (Methods in the Data Supplement). Pre-and postprocedural coronary angiograms were analyzed. To calculate the Synergy Between PCI With Taxus and Cardiac Surgery score (SYNTAX), each coronary lesion with ≥50% diameter stenosis in vessels ≥1.5 mm was scored using the algorithm fully described elsewhere. 10 A residual SYNTAX score was determined for the remaining lesions after completion of PCI. All cine coronary angiograms were reviewed and analyzed quantitatively at the angiographic core laboratory (Cardiac and Vascular Center, Samsung Medical Center, Seoul, Korea) with an automated edge-detection system (Centricity CA 1000; GE, Waukesha, WI). Two experienced technicians who were blinded to patient information reviewed the cine angiograms 11 ; interobserver variability was 0.81 (0.73-0.87), and intraobserver variability was 0.97 (0.97-0.98).
Outcomes and Definitions
The primary outcome was major adverse cardiac and cerebrovascular events (MACCE) defined as a composite of cardiac death, myocardial infarction, any repeat revascularization, or stroke during the follow-up period. The secondary outcomes were all-cause death, cardiac death, myocardial infarction, any repeat coronary revascularization, target lesion revascularization (TLR), non-TLR, and stroke. A detail description of the study outcomes is presented in Methods in the Data Supplement.
Diabetic patients were defined as patients who had been treated with oral hypoglycemic agents or insulin or those with HbA1c>6.5% at baseline, based on the current guidelines. 12 If the diagnosis of diabetes mellitus was uncertain based on registry data, the patient's medical chart was reviewed. According to the recommendation from the American Diabetes Association, diabetic patients were divided into 2 groups based on HbA1c measured at 2 years after PCI: HbA1c<7.0 and HbA1c≥7.0.
12,13
Statistical Analysis
Continuous variables were presented as mean±standard deviation, and differences were assessed by independent t test or Wilcoxon rank-sum test. Categorical variables were described as a number (n) with percentage (%), and differences were analyzed by Pearson χ 2 or Fisher exact
WHAT IS KNOWN
• It is not known if glycemic control after percutaneous coronary intervention (PCI) can improve cardiovascular outcomes.
• Because diabetic patients account for more than a quarter of all patients undergoing PCI and have worse outcomes compared with nondiabetic patients, determining the optimal strategy for glycemic control in diabetic patients after PCI has substantial clinical implications.
WHAT THE STUDY ADDS
• High HbA1c levels 2 years after PCI may identify a population at increased risk of adverse events, especially repeat revascularization. test. The Cox proportional hazard model was used to compare the risks of clinical outcomes between the 2 groups. We included covariates that were statistically significant on univariate analysis or those that were clinically relevant in the multivariate analysis: age, body mass index, sex, smoking status, hypertension, dyslipidemia, history of prior myocardial infarction, history of prior stroke, history of prior chronic kidney disease, left ventricular ejection fraction, baseline glycohemoglobin A, lesion type B2/C, multivessel disease, stent type, and residual SYNTAX score. Survival curves were constructed using Kaplan-Meier estimates for time to the first event and compared using a log-rank test. Propensity score-matched analysis was performed, and detail matching method is described in Methods in the Data Supplement. All tests were 2-tailed, and P<0.05 was considered statistically significant. All analyses were performed with the Statistical Analysis Software package (SAS version 9.2; SAS Institute, Cary, NC).
Results
Baseline and Angiographic Characteristics
At 2 years after PCI (median 717.6 days, interquartile range 688.3-745.1 days), HbA1c was <7.0 in 489 patients (mean 6.9%) and ≥7.0 in 491 patients (mean 7.9%). Baseline characteristics and angiographic findings are listed in Table 1 . Mean HbA1c at baseline was lower in the HbA1c<7.0 group than in the HbA1c≥7.0 group. In angiographic findings, the number of patients who had multivessel disease was fewer in the HbA1c<7.0 group than in the HbA1c≥7.0 group. Degree of revascularization assessed by residual SYNTAX score was not different between the groups. After propensity score-matched analysis, a total of 322 matched patient pairs were created. The C statistics for the propensity score model was 0.76. There were no significant differences in baseline and angiographic characteristics between the 2 groups in the propensity score-matched population. Mean low-density lipoprotein cholesterol level achieved at 24 months was not significantly different between the 2 groups in both total and propensity score-matched population. HbA1c levels were similar between the 2 groups at baseline, but significantly different at 1 year after the index procedure and remained stable thereafter Values are mean±standard deviation or n (%). All variables were considered as covariates of propensity score matching analysis except glucose-lowering drugs. ACC/ AHA indicates American College of Cardiology/American Heart Association; ACEi/ARB, angiotensin-converting enzyme inhibitor or aldosterone receptor blocker; BMI, body mass index; CKD, chronic kidney disease; CrCl, creatinine clearance; CVD, cardiovascular disease; DES, drug-eluting stent; DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitor; HbA1c, glycosylated hemoglobin A; HTN, hypertension; LAD, left anterior descending coronary artery; LCX, left circumflex artery; LDL-C, low-density lipoprotein cholesterol; LM, left main coronary artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; and SYNTAX, Synergy Between PCI With Taxus and Cardiac Surgery.
*LDL-C was measured in 905 patients. †Total implanted stent length. ‡Average implanted stent diameter. 
Clinical Outcomes of Overall Population
The median follow-up duration was 5.4 years (interquartile range, 3.6-7.5). The 7-year incidence of MACCE was 26.9% (108 patients) for the HbA1c<7.0 group and 40.3% (153 patients) for the HbA1c≥7.0 group (Table 2 and Figure 3) . The landmark analysis showed that the incidence of MACCE was not significantly different between the 2 groups during the first 2 years after PCI (P=0.28), and the difference was significant from 2 years (P<0.001; Figure 4 ). When we compare the incidence of MACCE based on the 1-year HbA1c, the difference between the 2 groups was consistent (P=0.01, Figure I in the Data Supplement). 
Clinical Outcomes of Propensity Score-Matched Population
Subgroup Analysis
To confirm the association between HbA1c measured 2 years after PCI and improved clinical outcomes across various subgroups, we performed post hoc subgroup analyses. The effect of glycemic control was consistent across various subgroups irrespective of baseline HbA1c or insulin treatment (Figures 6  and 7) . Especially, in propensity score-matched population, an interaction was found between HbA1c measured 2 years after PCI and the degree of revascularization (P for interaction =0.004). The benefit of the HbA1c<7.0 group was more prominent among patients with residual SYNTAX score ≥4 (median value of this study) than among patients with residual SYN-TAX score <4. When we compared the MACCE rates between the HbA1c<7.0 group and the HbA1c≥7.0 group after stratification according to the low-density lipoprotein cholesterol level achieved at 24 months, HbA1c<7.0 was still significantly associated with improvement of MACCE ( Figure 8 ).
Discussion
In this single-center observational study, we investigated the association between glycemic control status after PCI with DES and long-term clinical outcomes in patients with type 2 diabetes mellitus. Glycemic control, as reflected by HbA1c measured 2 years after PCI, was associated with improved clinical outcomes: the HbA1c<7.0 group had a lower rate of MACCE than the HbA1c≥7.0 group during a Values expressed are n (%) or hazard ratio (95% confidence interval). The percentages shown are Kaplan-Meier estimates from the intention to treat analysis. CI indicates confidence interval; HbA1c, glycosylated hemoglobin A; HR, hazard ratio; MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction; SYNTAX, Synergy Between PCI With Taxus and Cardiac Surgery; and TLR, target lesion revascularization.
*Hazard ratio was adjusted with age, body mass index, sex, smoker, hypertension, dyslipidemia, history of prior myocardial infarction, history of prior stroke, history of prior chronic kidney disease, left ventricular ejection fraction, baseline glycosylated hemoglobin A, lesion type B2/C, multivessel disease, stent type, and residual SYNTAX score.
†Major adverse cardiac and cerebrovascular events included cardiac death, myocardial infarction, repeat revascularization, and stroke. Glycemic Control After PCI in DM median follow-up of 5.4 years. This was mainly because of a decrease in repeat revascularization. In subgroup analysis, the treatment effect was consistent across various subgroups irrespective of baseline HbA1c or insulin treatment, but was more prominent in patients undergoing incomplete revascularization.
Diabetic patients represent a substantial proportion of patients undergoing PCI and have worse outcomes than nondiabetic patients.
14 Determination of the optimal strategy for glycemic control in those patients has important clinical implications. However, there is a paucity of data regarding the effect of glucose control on long-term A few studies have investigated the association between HbA1c at the time of PCI and clinical outcomes in diabetic patients. 15, 16 Glycemic control status before or at the time of PCI can be associated with prognosis after PCI; however, a more important issue is whether glycemic control after PCI can reduce cardiovascular events. In the present study, to reflect the stabilized and long-term status of glycemic control, we chose HbA1c measured 2 years after PCI upon which we divided the study population into the HbA1c<7.0 group and the HbA1c≥7.0 group. Among the propensity score-matched population, HbA1c levels in the 2 groups were similar at baseline but significantly different 2 years after the index procedure. The benefit of glycemic control was maintained after multivariable analysis and propensity score-matched analysis and was consistent regardless of baseline HbA1c level in subgroup analysis. Taken together, our results suggest that glycemic control after PCI may improve long-term outcomes in patients with diabetes mellitus independent of HbA1c level at the time of PCI. We think that our study adds new and important information on strategies for glycemic control after PCI in diabetic patients.
To date, there have been few studies on the association between HbA1c during follow-up after PCI and clinical outcomes. Ike et al 6 suggested that glycemic control started at PCI was not associated with an improvement in the long-term outcome. However, the number of patients was relatively small, and the follow-up duration was <1 year. In addition, the timing of follow-up HbA1c measurement was not clearly stated, and most importantly, glycemic control was assessed by the change between preprocedural HbA1c and follow-up HbA1c level rather than the follow-up HbA1c level per se. Therefore, patients with high follow-up HbA1c would be classified as the control group if the follow-up HbA1c level was lower than the baseline level. Kassaian et al 17 reported an association between good glycemic control (HbA1c levels ≤7.0%) and positive clinical outcomes after PCI. However, definite conclusions on the effects of glycemic control on long-term outcomes cannot be drawn because of the extremely low event rates and short follow-up duration. In contrast to previous studies, a relatively large sample size and long-term follow-up period give strength to our study. In addition, we performed propensity score-matched analyses to adjust for differences in baseline characteristics and subgroup analyses to show that the effect of glycemic control was consistent across various subgroups.
It is worthwhile to compare the results of our studies with those of recent major clinical trials. In the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes), the VADT (Veterans Affairs Diabetes Trials), and the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation), intensive glucose control had no benefit on the rate of major cardiovascular events. 3, 5, 18 Different enrollment criteria or baseline characteristics of the subjects may explain the discrepant results between our study and these 3 major trials. First, we included only patients undergoing PCI with DES, whereas the majority of patients in these trials did not have any previous cardiovascular events, and patients with recent cardiovascular events were excluded. Second, patients in our study had a lower baseline HbA1c level and a lower rate of insulin use compared with those enrolled in the above 3 trials. Duration of diabetes mellitus was ≈10 years in the VADT and ACCORD trials and 8 years in the ADVANCE trial. Therefore, patients in the 3 trials might have more advanced diabetes mellitus than our patients, although we did not have specific data on the diabetic duration. Taken together, the effects of glucose control in type 2 diabetes mellitus may differ according to patient characteristics, such as recent cardiovascular events, glycemic control status, and duration of diabetes mellitus.
In the present study, the benefit of glycemic control on the MACCE was mainly because of a reduction in repeat revascularization. Although the second-generation DES improves clinical outcomes compared with first-generation DES and bare-metal stents after PCI, 19 diabetes mellitus is still one of the most important risk factors for restenosis across the spectrum of stent devices. 20 In randomized Figure 4 . Two-year landmark analysis for the primary outcome. MACCE rates in (A) overall population and (B) propensity score-matched population. HbA1c indicates glycosylated hemoglobin A; MACCE, major adverse cardiac and cerebrovascular events; and PCI, percutaneous coronary intervention. Glycemic Control After PCI in DM trials, the second-generation DES failed to reduce TLR or target lesion failure in diabetic patients compared with the first-generation DES. 21 Therefore, there is still a substantial need to reduce restenosis and TLR in diabetic patients. In our study, association between glucose control and improved outcomes was consistent without regard to type of DES. Another important finding was that non-TLR was significantly reduced in the HbA1c<7.0 group compared with the HbA1c≥7.0 group. In patients undergoing PCI, major adverse cardiovascular events occurring during follow-up could be equally attributed to recurrence at the site of both culprit and nonculprit lesions. 22 Moreover, the cumulative event rate of nonculprit lesions in diabetic patients was higher in patients with diabetes mellitus than in those without diabetes mellitus. 23 Therefore, reduction of non-TLR is an important factor in improving the rate of cardiovascular events in diabetic patients, and glucose control may be the appropriate treatment strategy in this respect. Of note, the benefit of glucose control was more prominent in patients with residual SYNTAX score ≥4.
In the present study, survival curves of the MACCE diverged from 1 to 2 years after the index procedure. There are 2 possible explanations for late benefit. First, according to the recent long-term follow-up study, DES-related events continuously occur during follow-up period even several years after the index procedure. 24 Second, there was significant difference in non-TLR between the 2 groups. However, determination of duration of therapy needed to demonstrate this benefit is difficult and beyond the scope of our study. In our opinion, treatment for adequate glycemic control needs to be continued indefinitely.
Limitations
There are several limitations in this study. First, the study was a nonrandomized observational study. Although we performed propensity score-matched analysis to adjust for potential confounding factors, we did not correct for all possible and unmeasured variables, such as smoking cessation by the matching technique. Because propensity matching was used for achieved HbA1c levels, not for treatment of interest, a cautious interpretation is needed. Second, only patients who had HbA1c data at both baseline and 2 years were selected for analysis, which might lead to selection bias. Third, the long-term data about lipid-lowering regimen, such as statin intensity and dosage, was limited, and low-density lipoprotein cholesterol level during followup was not available in 75 patients (7.7%). Fourth, we did not have detailed information about time-dependent factors to capture new risk factors that emerged during follow-up. Finally, we did not know the exact duration of diabetes mellitus, which might be a major contributor to the difference in treatment effect between the recent major clinical trials of glycemic control in patients with type 2 diabetes mellitus. 4, 25, 26 
Conclusions
HbA1c measured at 2 years after PCI was associated with the rate of MACCE: MACCE occurred less frequently in patients with HbA1c<7.0 than in those with HbA1c≥7.0 measured 2 years after the index intervention. This effect was mainly because of a reduction in repeat revascularization. Our data suggest that high HbA1c levels 2 years after PCI may identify a population at increased risk of adverse events, especially repeat revascularization. Further study is warranted 
